Terumo Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Hikaru Samejima

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO

Hikaru Samejima (59 yo)

no data

Tenure

Mr. Hikaru Samejima serves as Director of Terumo Corporation since February 7, 2024. He serves as President and CEO of Terumo Corporation since April 1, 2024. He served as Group Senior Managing Executive O...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shinjiro Sato	Corporate Advisor & Director	no data	JP¥169.00m	0.0099% ¥ 385.3m
Hikaru Samejima	President	no data	no data	no data
Jin Hagimoto	CFO, CIO	less than a year	no data	no data
Shinji Omori	CTO, GM of DX Promotion Dept. R&D Division and Executive Officer	less than a year	no data	no data
Miho Mizuguchi	Executive Officer	8yrs	no data	no data
Tomoko Adachi	Chief Human Resources Officer & Group Executive Officer	1.3yrs	no data	no data
Shoji Hatano	Director & Corporate Advisor	less than a year	no data	0.0035% ¥ 136.8m
James Rushworth	Group Executive Officer & Chief Commercial Officer	1.3yrs	no data	no data
Kazunori Hirose	Director & Group Managing Executive Officer	no data	no data	0.0018% ¥ 70.2m
Itaru Sakaguchi	Group Managing Executive Officer	less than a year	no data	no data
Toshihiko Osada	Group Senior Managing Executive Officer	no data	no data	no data
Fumihisa Hirose	Group Managing Executive Officer	less than a year	no data	no data

0.3yrs

Average Tenure

61yo

Average Age

Experienced Management: 4543's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Shinjiro Sato	Corporate Advisor & Director	9.8yrs	JP¥169.00m	0.0099% ¥ 385.3m
Hikaru Samejima	President	less than a year	no data	no data
Shoji Hatano	Director & Corporate Advisor	7.8yrs	no data	0.0035% ¥ 136.8m
Kazunori Hirose	Director & Group Managing Executive Officer	2.3yrs	no data	0.0018% ¥ 70.2m
Norimasa Kunimoto	Director & Group Managing Executive Officer	less than a year	no data	0.0021% ¥ 81.8m
Soichiro Uno	Independent Outside Director	4.8yrs	no data	no data
Hidenori Nishi	Independent Outside Director	3.8yrs	no data	0.00022% ¥ 8.5m
Yukiko Kuroda	Independent Outside Director	5.8yrs	no data	0.00010% ¥ 3.9m
Takanori Shibazaki	Director	2.8yrs	no data	0.0023% ¥ 88.8m
Toshiaki Takagi	Chairman of the Board & Group Managing Executive Officer	13.8yrs	JP¥131.00m	no data
Masaichi Nakamura	Independent Outside Director	4.8yrs	no data	0.00027% ¥ 10.5m
Keiya Ozawa	Independent Outside Director	2.8yrs	no data	0.000070% ¥ 2.7m

4.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 4543's board of directors are considered experienced (4.3 years average tenure).

Terumo Management

Management criteria checks 1/4

Key information

Recent management updates

Terumo Corporation, Annual General Meeting, Jun 26, 2024

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Recent updates

Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543)

Consensus EPS estimates increase by 11%

Price target increased by 7.4% to JP¥3,136

Terumo (TSE:4543) Has Announced A Dividend Of ¥22.00

New minor risk - Dividend sustainability

Upcoming dividend of JP¥22.00 per share

Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Is Terumo (TSE:4543) Using Too Much Debt?

Price target increased by 7.3% to JP¥5,548

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation, Annual General Meeting, Jun 26, 2024

Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023

Upcoming dividend of JP¥22.00 per share at 1.1% yield

Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023

Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥21.00 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023

Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥18.00 per share

Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543).

NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023

Less than half of directors are independent

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Full year 2022 earnings: EPS misses analyst expectations

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.

Less than half of directors are independent

Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥16.00 per share

Third quarter 2022 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥29.22 (vs JP¥23.63 in 2Q 2021)

Upcoming dividend of JP¥15.00 per share

First quarter 2022 earnings released: EPS JP¥36.90 (vs JP¥18.57 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020)

Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020)

Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022

Upcoming dividend of JP¥14.00 per share

New 90-day low: JP¥3,951

Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc.

Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd

New 90-day high: JP¥4,560

Terumo Corporation Revises Earnings Guidance for the Fourth Quarter of Fiscal 2021

Third quarter 2021 earnings released: EPS JP¥35.40 (vs JP¥28.22 in 3Q 2020)

Revenue and earnings beat expectations

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

Terumo Corporation to Report Q3, 2021 Results on Feb 04, 2021

Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for Dblg1 Automated Insulin Delivery Solution in Japanese Market

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

Terumo Corporation to Report Q2, 2021 Results on Nov 05, 2020

Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc.

Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million.

Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020

CEO